Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.
Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J
Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists.
Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J
An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry.
McCaffrey K, Boo I, Owczarek CM, Hardy MP, Perugini MA, Fabri L, Scotney P, Poumbourios P, Drummer HE
Hepatitis C
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE
Calsyntenin-1 mediates hepatitis C virus replication.
Awan Z, Tay ESE, Eyre NS, Wu LE, Beard MR, Boo I, Drummer HE, George J, Douglas MW
Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.
Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, Das S, Boo I, Drummer H, Bock CT, Gowans EJ, Jackson DC, Torresi J